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of 12 months and cycle lengths of 1 month was designed
to evaluate the cumulative costs over time of plastic and
metal stent. A meta-analysis of all published randomised
trials was performed to derive the transitional probabili-
ties for ﬁrst and second occlusion and for death. A
national health care perspective was adopted. Unit cost
data was obtained from available public sources in
France, Sweden and England. Resource use was derived
from expert opinions in each country. RESULTS: Initial
procedural costs were higher with metal than with plastic
stents: the cost difference was €953 for Sweden, €739 for
France and €653 for England. However, due to fewer
reinterventions for exchange, follow-up costs were sub-
stantially reduced with metal stents. In Sweden and
England, the cost break-even point was after 4 months
and for patients with longer survival, metal stents became
cost-saving. In France, the break-even point was after 5
months. At 12 months, the difference per patient cost in
favour of metal was €493 for France, €620 for England
and €1002 for Sweden. CONCLUSION: This analysis
demonstrates that initial metal stent placement can be a
cost-saving strategy, especially if the patient survives 
more than 4 to 5 months. The higher procedural cost 
with a metal stent is offset by a reduction in re-treatment
costs. Avoiding reinterventions will beneﬁt patients in
terms of quality of life and the health care system as a
whole.
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OBJECTIVES: With a prevalence of 10% asthma is the
most common chronic disease among children and ado-
lescents in Germany. Approaches to reduce the burden of
asthma comprise patient education as a well-recognised
and effective component that helps to improve self-
management skills. We determined whether a continuous
internet-based education programme (IEP) as an add-on
to traditional education improves health outcomes of
asthma patients (8–16 years) at a favourable beneﬁt-cost
ratio. METHODS: We performed a prospective cost-
beneﬁt analysis alongside a non-randomised trial. A total
of 438 patients in 34 study centres in Germany were
enrolled in the investigation. Study participants were
assigned to a control group and two intervention groups.
Patients in both intervention groups received traditional
patient education. In one group patients received addi-
tional self-management education through the IEP for the
duration of 6 months. At the initial visit and at 6 and 12
months health service utilisation data were collected.
RESULTS: Utilisation of various Health care services (e.g.
number of consultations, urgent medical examinations)
decreased signiﬁcantly in both intervention groups. In the
ﬁrst year after intervention traditional education realised
morbidity cost savings of 333 EUR per patient. Adding
the IEP provided incremental savings of €143. From a
payer perspective, the beneﬁt-cost ratio of the traditional
education programme was 0.45. Adding the IEP im-
proved the ratio (0.69). For patients with moderate or
severe asthma the beneﬁt-cost ratio were 1.07 and 1.42
(with IEP). In individuals who had experienced an emer-
gency visit due to asthma 6 months prior to the study
entry, the ratios were 1.11 and 1.21, respectively. CON-
CLUSIONS: As a supplementary to traditional asthma
education programmes, the IEP offers the potential to
realise incremental morbidity savings. Subgroup analyses
demonstrated that within 1-year morbidity cost savings
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OBJECTIVES: Patients who survived an acute myocar-
dial infarction (MI) have an increased risk for subsequent
major cardiovascular events and cardiac (often sudden)
death. The use of highly puriﬁed omega-3 polyunsatu-
rated fatty acids (n-3 PUFAs) in addition to standard 
secondary prevention after MI was associated with a sig-
niﬁcant reduction in risk of sudden death. Our study
assessed the cost-effectiveness (CE) of adding n-3 PUFAs
treatment to the current secondary prevention treatment
after acute MI in Belgium. METHODS: Based on the clin-
ical outcomes of the GISSI-prevenzione study (MI, stroke,
revascularisation rate and mortality) a decision model
was built in DataTM Pro. Adding n-3 PUFAs to standard
treatment was compared to standard treatment alone in
patients with a recent history of MI (age = 59 years) from
the health care payer’s perspective. The time horizon 
of the model was 3.5 years (identical to the GISSI-
prevenzione study). The cost of non-fatal events was
based on Belgian literature data and the cost of cardiac
death on a patient chart review (n = 60). The unit cost of
n-3 PUFAs was €1.25. Life expectancy data for cardiac
disease were obtained from published sources and
adjusted to the Belgian population. Results are expressed
as cost (€) per life year gained (LYG). RESULTS: Treat-
ment with n-3 PUFAs results in 0.287 life years gained at
